Literature DB >> 33070092

Selection and characterization of specific nanobody against neuropilin-1 for inhibition of angiogenesis.

Shamsi Naderi1, Reyhaneh Roshan1, Hajarsadat Ghaderi1, Mahdi Behdani2, Sara Mahmoudi1, Mahdi Habibi-Anbouhi3, Mohammad Ali Shokrgozar3, Fatemeh Kazemi-Lomedasht4.   

Abstract

Neuropilin-1 (NRP-1), non-tyrosine kinase receptor, was initially identified as axonal protein and later recognized as co-receptor for vascular endothelial growth factor (VEGF). Neuropilins (NRPs) are involved in vascular development and tumor angiogenesis. Over the last years, many studies have been accomplished to inhibit angiogenesis. In this study, the nanobody library was panned against immobilized NRP-1 antigen. High affinity and specificity nanobodies were selected through monoclonal ELISA. The selected nanobodies inhibited proliferation and tube formation of HUVEC and MCF-7 cells in vitro and ex vivo. The results highlight potential of anti-NRP1 nanobodies in inhibition of angiogenesis both in vitro and ex vivo and promises development of novel therapeutics against pathologic angiogenesis.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; NRP-1; Nanobody; VEGF

Mesh:

Substances:

Year:  2020        PMID: 33070092     DOI: 10.1016/j.molimm.2020.10.004

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  1 in total

1.  Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies.

Authors:  Elmira Karami; Shamsi Naderi; Reyhaneh Roshan; Mahdi Behdani; Fatemeh Kazemi-Lomedasht
Journal:  Cancer Chemother Pharmacol       Date:  2022-01-06       Impact factor: 3.288

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.